QNRX 8-K
Quoin Pharmaceuticals, Ltd. (QNRX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
| (Translation of registrant’s name into English) |
| State of |
||||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
|
|
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
| Not applicable |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Ordinary Shares, no par value per share* | N/A |
| * | Not for trading, but only in connection with the registration of the American Depositary Shares pursuant to requirements of the Securities and Exchange Commission. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Changes to 401(k) Plan
Quoin Pharmaceuticals Ltd. (“we,” “us,” or the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual Meeting”) on August 20, 2026. At the Annual Meeting, shareholders approved changes to the matching contributions payable pursuant to the Company’s 401(k) plan, including to the Company’s U.S.-based executive officers. A summary of the changes to such 401(k) Plan is incorporated herein by reference from page 26 of the Company’s definitive proxy statement on Schedule 14A for the Annual Meeting, which was filed on July 16, 2026, with the Securities and Exchange Commission (the “Proxy Statement”).
Item 5.07. Submission of Matters to a Vote of Security Holders.
During the Annual Meeting, on August 20, 2026, shareholders were asked to consider and vote upon five proposals. These matters are described in detail in the Proxy Statement.
On the record date of July 15, 2026, there were 70,294,615 ordinary shares issued and outstanding and entitled to vote at the Annual Meeting, represented by 2,008,418 ADSs. For each proposal, the results of the shareholder voting were as follows:
| 1. | The shareholders elected the following directors to serve as a director of the Company until the Company’s next annual general meeting of shareholders and until such director’s successor is duly elected and qualified, or until such director’s earlier resignation or retirement, based upon the following votes: |
| Directors | For | Against | Abstain | Broker Non-Votes |
| Dr. Michael Myers | 19,774,790 | 114,660 | 10,850 | 16,285,325 |
| Denise Carter | 19,432,490 | 456,715 | 10,885 | 16,285,535 |
| Joseph Cooper | 19,425,385 | 464,030 | 10,885 | 16,285,325 |
| James Culverwell | 19,425,315 | 464,100 | 10,885 | 16,285,325 |
| Dr. Dennis H. Langer | 19,425,595 | 463,820 | 10,885 | 16,285,325 |
| Natalie Leong | 16,807,490 | 3,081,925 | 10,885 | 16,285,325 |
| Michael Sember | 19,425,385 | 464,030 | 10,885 | 16,285,325 |
| 2. | The shareholders approved, on an advisory basis, the terms of the compensation of the Company’s named executive officers, as described in the Proxy Statement, based upon the following votes: |
| For | Against | Abstain | Broker Non-Votes |
| 18,127,445 | 556,430 | 1,216,425 | 16,285,325 |
| 3. | The shareholders approved changes to the Company’s non-employee directors’ compensation program, as described in the Proxy Statement, based upon the following votes: |
| For | Against | Abstain | Broker Non-Votes |
| 16,365,160 | 3,517,080 | 18,060 | 16,285,325 |
| 4. | The shareholders approved changes to the matching contributions payable pursuant to the Company’s 401(k) plan, including to the Company’s U.S.-based executive officers, as described in the Proxy Statement, based upon the following votes: |
| For | Against | Abstain | Broker Non-Votes |
| 19,245,870 | 623,070 | 24,465 | 16,292,220 |
| 5. | The appointment of CBIZ CPAs P.C. to serve as the Company’s independent registered public accounting firm until the Company’s next annual general meeting of shareholders, based upon the following votes: |
| For | Against | Abstain | Broker Non-Votes |
| 35,488,320 | 697,130 | 175 | 0 |
Item 8.01. Other Events.
At the Annual Meeting, shareholders approved certain amendments to the Company’s non-employee directors’ compensation program (the “NED Program”), which was previously approved by the Company’s shareholders at the Annual General Meeting held on April 12, 2022 (the “2022 AGM”) and the amendments to the NED Program that were approved by our shareholders at the annual shareholder meetings held in 2023, 2024 and 2025. The amendments to the NED Program approved at the Annual Meeting provide that (i) the annual base retainer be increased to up to $250,000, which amount shall be determined annually at the discretion of the Compensation Committee and the Board; and (ii) the range of values for the annual award of options be increased to no less than $20,000 and no more than $200,000, with such value being determined annually at the discretion of the Compensation Committee and the Board. The remaining terms set forth in the NED Program, as approved at the 2022 AGM and as amended to date, remain unchanged.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Date: August 20, 2026 | QUOIN PHARMACEUTICALS LTD. | |
| By: | /s/ Sally Lawlor | |
| Name: | Sally Lawlor | |
| Title: | Chief Financial Officer | |